Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 19/20 | 1.00 |
| ▸ | USP47 | Q96K76 | 15/20 | 1.00 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680255 | 0.89 | USP7 (0.80) | USP7USP47 | |
| SCHEMBL2680693 | 0.89 | USP7 (0.80) | USP7USP47 | |
| SCHEMBL2681334 | 0.88 | USP7 (0.78) | USP7USP47 | |
| SCHEMBL2680308 | 0.87 | USP7 (0.77) | USP7USP47 | |
| SCHEMBL2682324 | 0.87 | USP7 (0.77) | USP7USP47 | |
| SCHEMBL2680271 | 0.86 | USP7 (1.00) | USP7USP47PADI4 | |
| SCHEMBL2680278 | 0.85 | USP7 (0.73) | USP7USP47 | |
| SCHEMBL2680714 | 0.84 | USP7 (0.74) | USP7USP47PADI4 | |
| SCHEMBL2680803 | 0.84 | USP7 (0.72) | USP7USP47 | |
| SCHEMBL2680847 | 0.84 | USP7 (0.72) | USP7USP47 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | claimed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | claimed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | claimed |
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | USP7 437/4885USP47 315/4885PADI4 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.